Genentech, a member of the Roche Group, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in South San Francisco, US. Founded in 1976, the company has pioneered advancements in biotechnology, focusing on the development of innovative medicines for serious medical conditions, particularly in oncology, immunology, and neuroscience.
With a strong commitment to research and development, Genentech has introduced several groundbreaking therapies, including targeted treatments that have transformed patient care. Its unique approach to drug development, emphasising personalised medicine, has solidified its position as a market leader. Notable achievements include being one of the first biotechnology companies to successfully bring a monoclonal antibody to market, setting a benchmark for the industry. Genentech continues to drive progress in healthcare, making significant contributions to the global pharmaceutical landscape.
+6 vs industry average
Genentech’s score of 45 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Genentech?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
Scope 3 accounts for ••• of total emissions.
Genentech's reported carbon emissions
Genentech, a Pharmaceutical Preparation Manufacturing company based in the US, has disclosed its carbon emissions data across various scopes.
For 2019, Genentech reported total global emissions of approximately 254.38 million kg CO2e. This included Scope 1 emissions totalling about 73.18 million kg CO2e, Scope 2 (location-based) at approximately 63.44 million kg CO2e, and Scope 3 emissions of about 73.60 million kg CO2e.
In 2018, the company's total global emissions were approximately 278.10 million kg CO2e, with Scope 1 at 78.05 million kg CO2e, Scope 2 (location-based) at 67.79 million kg CO2e, and Scope 3 at 65.96 million kg CO2e.
Looking back, Genentech reported total global emissions of approximately 205.76 million kg CO2e in 2010.
Genentech has set a near-term reduction target aiming for a 30% absolute reduction in CO2 emissions from its onsite energy use by 2020, compared to 2010 levels.
The emissions data for Genentech is inherited from its parent company, Roche Holding AG.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Genentech’s Climate Goals (2030 & 2050)
1 goal2020
30% reduction in all scopes
We're targeting a 30% absolute reduction in CO2 emissions from our onsite energy use, compared to 2010 levels.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 1 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
2 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives

Science Based Targets Initiative
Inherited from Roche Holding AG
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project